Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 LAMEA Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. LAMEA Castrate-resistant Prostate Cancer Market by Therapy
4.1 LAMEA Hormonal Therapy Market by Country
4.2 LAMEA Immunotherapy Market by Country
4.3 LAMEA Chemotherapy Market by Country
4.4 LAMEA Radiotherapy Market by Country
Chapter 5. LAMEA Castrate-resistant Prostate Cancer Market by Country
5.1 Brazil Castrate-resistant Prostate Cancer Market
5.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
5.2 Argentina Castrate-resistant Prostate Cancer Market
5.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
5.3 UAE Castrate-resistant Prostate Cancer Market
5.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
5.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
5.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
5.5 South Africa Castrate-resistant Prostate Cancer Market
5.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
5.6 Nigeria Castrate-resistant Prostate Cancer Market
5.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
5.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
5.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
Unique Offerings 